A stock falling 30% doesn’t automatically make it cheap.

That’s probably the most important principle to remember while looking at the current FMCG correction.

If a stock trading at 80 times earnings falls 25%, it may simply move from ridiculously expensive to very expensive.

On the other hand, if a high-quality business falls sharply while its underlying economics remain intact, the correction can create exactly the sort of opportunity long-term investors wait years to find.

After examining why the FMCG sector is being de-rated in Part 1, let’s now ask the question that actually matters for investors:

Where is genuine value emerging?

Start with the numbers

The valuation dispersion across the sector is extraordinary.

Company	P/E	EV/EBITDA	ROE	1Y Return	3Y Sales Growth	3Y Profit Growth	Latest Qtr Sales	Latest Qtr Profit
ITC	16.8x	11.7x	29.3%	-35.1%	3.6%	3.0%	-11.1%	-22.0%
Emami	21.2x	15.0x	26.2%	-33.9%	3.5%	5.2%	+15.0%	-16.4%
Jyothy Labs	26.5x	16.0x	21.7%	-39.1%	5.9%	13.7%	+3.0%	-50.8%
Dabur	34.2x	21.8x	17.0%	-25.9%	4.6%	3.7%	+10.6%	+15.0%
Gillette India	35.6x	23.8x	66.5%	-27.5%	11.2%	31.3%	+10.8%	+9.4%
Colgate	35.9x	24.0x	82.7%	-21.7%	4.9%	8.4%	+11.8%	+7.8%
Varun Beverages	41.1x	23.1x	16.2%	-15.0%	18.1%	24.0%	+20.4%	+15.5%
HUL	42.4x	29.0x	31.0%	-21.0%	2.1%	14.4%	+10.1%	-3.7%
Godrej Consumer	44.5x	27.4x	16.1%	-26.4%	4.5%	4.7%	+15.4%	+10.6%
Britannia	48.7x	33.4x	53.5%	-8.9%	5.5%	7.6%	+8.2%	+13.6%
Mrs Bectors	54.4x	26.0x	10.4%	-15.6%	14.5%	15.6%	+15.7%	+41.8%
Marico	57.1x	40.1x	42.8%	+14.3%	11.7%	11.0%	+22.9%	+25.0%
Tata Consumer	61.9x	32.7x	7.4%	-2.3%	13.8%	12.5%	+11.9%	+27.8%
Nestlé India	74.0x	47.7x	73.2%	+25.8%	11.1%	13.1%	+25.2%	+48.6%

The first thing I notice isn’t which stock has fallen the most.

It’s how dramatically the relationship between valuation and growth differs from company to company.

And that is where potential opportunities emerge.

1. ITC — the clearest value opportunity

ITC immediately stands apart from everything else in the table.

At approximately 16.8 times earnings and 11.7 times EV/EBITDA, it trades at a fraction of the valuation assigned to most consumer businesses.

Yet ROE remains a healthy 29.3%.

The obvious question is:

Why is it so cheap?

Because the market isn’t irrational.

ITC’s cigarette business faces significant taxation and regulatory risk, and recent earnings have been weak. The screen shows quarterly sales declining 11% and profit falling 22%, although consolidated comparisons need care because ITC’s business mix and cigarette-tax changes can distort the headline figures.

Meanwhile, its historical three-year growth isn’t particularly impressive either.

Sales growth is approximately 3.6%, while profit growth is around 3%.

But the non-cigarette FMCG business presents a much more interesting picture.

Brands such as Aashirvaad, Sunfeast, Bingo!, YiPPee!, Savlon and Fiama have created a sizeable consumer platform that could become increasingly valuable if margins continue improving.

So ITC offers something that is becoming rare in Indian consumer investing:

Quality without an enormous valuation premium.

You don’t need ITC to grow earnings at 20% for the investment thesis to work.

If the business eventually delivers moderate earnings growth while maintaining healthy dividends and its valuation normalises even modestly, shareholder returns could be respectable.

Verdict: One of the strongest value opportunities created by the FMCG de-rating.

2. Gillette India — the hidden quality opportunity

Gillette may be the most interesting stock revealed by our screen.

Consider the numbers:

P/E: 35.6x
ROE: 66.5%
3-year sales growth: 11.2%
3-year profit growth: 31.3%
Latest-quarter sales growth: 10.8%
Latest-quarter profit growth: 9.4%
1-year correction: 27.5%

That is an unusual combination.

Thirty-five times earnings isn’t conventionally cheap.

But valuation should always be considered relative to business quality and growth.

Gillette’s ROE of more than 66% indicates extraordinary capital efficiency. More importantly, profits have compounded much faster than those of most traditional FMCG companies in our comparison.

Yet the stock trades at less than half Nestlé India’s P/E.

Gillette also operates in categories where brand trust, product quality and habitual purchasing behaviour create substantial barriers.

The weakness is diversification.

Its business is considerably narrower than HUL, ITC or Dabur. Category concentration therefore deserves a valuation discount.

Nevertheless, after the correction, Gillette India may be one of the most attractive quality-growth combinations in the FMCG universe.

Verdict: Perhaps the most interesting overlooked quality bet.

3. HUL — the company everyone wants, but at what price?

Hindustan Unilever is arguably the benchmark against which Indian FMCG companies are measured.

Its collection of brands, distribution reach, cash generation and balance-sheet quality remain exceptional.

But that doesn’t automatically make HUL stock attractive.

At the valuation shown in our screen — approximately 42 times earnings — the stock is cheaper than it used to be but still not objectively cheap.

The bigger concern is growth.

Three-year sales growth in the screen is only around 2.1%.

The latest quarter improved considerably, with revenue growing approximately 10%, but profit declined modestly.

Therefore, investors buying HUL today are essentially betting that growth normalises over the coming years.

If HUL can sustainably return to stronger volume and earnings growth, today’s valuation may prove reasonable.

But if earnings settle into a high-single-digit trajectory, further P/E compression remains possible.

This is exactly why I would distinguish between:

Great business and great investment opportunity.

HUL unquestionably belongs in the first category.

Whether it belongs in the second depends on the price.

Verdict: Excellent long-term core holding, but valuation discipline remains necessary.

4. Dabur — a turnaround rather than a classic compounder

Dabur is beginning to look interesting after falling approximately 26%.

At around 34 times earnings, its valuation is far below the extreme multiples associated with Nestlé, Tata Consumer or Marico.

But again, there is a reason.

Three-year sales growth is only around 4.6%, while profit growth is approximately 3.7%.

Those are weak numbers for a company trading above 30 times earnings.

However, the latest quarter offers some encouragement.

Sales grew approximately 10.6%, while profit increased roughly 15%.

If that improvement continues, investors may eventually look back at the current correction as the period when Dabur’s earnings cycle bottomed.

The company retains strong brands across healthcare, oral care, hair care, beverages and Ayurvedic products.

The question isn’t whether those brands possess value.

It’s whether management can convert those brands into sustainable double-digit earnings growth again.

Verdict: An interesting turnaround candidate, but earnings recovery needs confirmation.

5. Emami — value is quietly appearing

Emami deserves much more attention after the correction.

The stock has fallen approximately 34% over one year and trades at just 21 times earnings.

Its ROE is around 26%.

That’s a very different setup from paying 50–70 times earnings for a consumer business.

But the historical growth numbers aren’t exciting:

3-year sales growth: 3.5%
3-year profit growth: 5.2%.

The latest quarter also shows an interesting divergence:

Sales grew approximately 15%, while profits declined around 16%.

This suggests the business needs margin normalisation.

But here’s the important difference.

At 21 times earnings, Emami doesn’t need to deliver spectacular growth to justify its valuation.

If margins recover and earnings eventually compound at high single digits or low double digits, the return equation could become attractive.

Verdict: An increasingly interesting value-oriented FMCG opportunity.

6. Varun Beverages — the growth alternative

Varun Beverages stands out for a completely different reason.

It isn’t cheap.

At approximately 41 times earnings, nobody would call it a traditional value stock.

But look at what investors receive for that valuation:

3-year sales growth: 18.1%
3-year profit growth: 24.0%
Latest-quarter sales growth: 20.4%
Latest-quarter profit growth: 15.5%.

Suddenly 41 times earnings looks considerably more reasonable compared with companies trading at 50–70 times earnings while growing substantially slower.

Varun Beverages isn’t directly comparable with HUL or Dabur because its bottling business has different capital intensity and economics.

Nevertheless, investors seeking growth at a somewhat rational valuation should probably examine VBL rather than automatically buying the traditional FMCG giants.

Verdict: One of the strongest growth-adjusted opportunities, although not a conventional defensive FMCG bet.

7. Jyothy Labs — falling the most doesn’t make it the cheapest

Jyothy Labs is an excellent example of why investors need to look beyond share-price corrections.

The stock has fallen approximately 39% in one year, the largest decline in our table.

Its P/E has consequently fallen to approximately 26.5 times.

At first glance, that looks attractive.

The company has an ROE around 22%, while three-year profit growth remains approximately 14%.

But the latest quarter demands attention.

Sales grew only around 3%, while profits collapsed approximately 51%.

That’s not a minor slowdown.

When profits fall sharply, the apparent P/E can become misleading because future earnings may be lower than trailing earnings.

In other words:

The “P” may have fallen, but the “E” can fall too.

Jyothy owns valuable brands and could eventually emerge as a turnaround opportunity.

But I’d prefer evidence of margin stabilisation before becoming aggressive.

Verdict: Watchlist candidate rather than immediate conviction buy.

What about Colgate?

Colgate is another fascinating case.

Its ROE of roughly 83% is the highest in our table.

That’s extraordinary.

The stock trades around 36 times earnings, significantly below Nestlé, Marico, Britannia and Tata Consumer.

The weakness is growth.

Three-year sales growth is approximately 5%, while profit growth is around 8%.

That makes Colgate similar to HUL in one important respect:

The business economics are exceptional, but growth needs to accelerate for meaningful re-rating.

At the right price, however, Colgate deserves serious consideration as a high-quality defensive compounder.

Why I’m not rushing into Nestlé

Nestlé may actually be one of the highest-quality businesses in the entire table.

ROE is approximately 73%.

Three-year sales growth is around 11%.

Three-year profit growth is approximately 13%.

And recent quarterly growth is extremely strong.

What’s not to like?

The price.

At approximately 74 times earnings and 48 times EV/EBITDA, investors are paying an enormous premium for those economics.

That leaves very little room for disappointment.

Nestlé can continue being a wonderful company while producing mediocre stock returns if its valuation eventually normalises.

Verdict: Wonderful company. Uncomfortable valuation.

Marico demonstrates the opposite side of the de-rating

Marico hasn’t really participated in the FMCG collapse.

The stock is actually up approximately 14% over one year in our screen.

There’s a reason.

Latest-quarter revenue growth is around 23%, while profit grew approximately 25%.

Three-year sales and profit growth are both around 11–12%.

The market is therefore rewarding execution.

But that success comes at approximately 57 times earnings.

I’d happily own Marico at the right valuation.

At today’s multiple, however, much of the good news appears already reflected in the price.

So where is the real opportunity?

After combining valuation, business quality, growth, return ratios and recent earnings trends, this is how I would currently classify the sector:

Rank	Company	Investment Thesis	Main Concern
🥇 ITC	Best value + margin of safety	Cigarette taxation/regulation
🥈 Gillette India	Best quality-growth-valuation combination	Portfolio concentration
🥉 HUL	Best diversified core FMCG franchise	Still not outright cheap
4	Dabur	Earnings-recovery potential	Weak historical growth
5	Emami	Low valuation + strong ROE	Margin/growth weakness
6	Varun Beverages	Strongest growth profile	Higher valuation/capital intensity
7	Colgate	Exceptional business economics	Moderate growth
👀	Jyothy Labs	Potential turnaround	Sharp earnings deterioration

The ranking could change substantially as quarterly results and valuations change.

That’s why buying simply because a stock has fallen 30% is dangerous.

The best strategy may be to wait for two things to meet

The ideal FMCG opportunity occurs when two trends intersect:

Valuation ↓

while

Earnings growth ↑

Buying while valuations are falling and earnings estimates are falling can produce a value trap.

Buying after earnings have fully recovered often means the stock has already re-rated.

The sweet spot lies somewhere between the two.

That’s why companies such as Dabur, Emami and Jyothy deserve monitoring.

And why HUL becomes increasingly interesting if its valuation continues compressing without deterioration in its franchise.

Conclusion: Great businesses are finally meeting valuation discipline

The FMCG de-rating is beginning to create opportunities, but investors shouldn’t treat the entire sector as cheap.

Nestlé at around 74 times earnings isn’t automatically cheap because other FMCG stocks have fallen.

Marico at 57 times earnings isn’t a bargain simply because it is a wonderful company.

Likewise, Jyothy Labs isn’t automatically attractive because its share price has collapsed nearly 40%.

Price has to be compared with earnings, growth and business quality.

That’s where the current correction becomes interesting.

ITC offers perhaps the strongest valuation protection.

Gillette India presents an unusually attractive combination of profitability, historical earnings growth and a substantially reduced valuation.

HUL remains the diversified FMCG franchise I’d be most comfortable owning for the long term, but I’d remain disciplined about the entry valuation.

Dabur and Emami offer potential recovery opportunities.

Varun Beverages provides a higher-growth alternative.

And Jyothy Labs deserves a place on the watchlist while investors wait for evidence that its earnings deterioration has bottomed.

The larger lesson from this correction goes well beyond FMCG:

Never confuse a great company with a great stock at any price.

The last decade rewarded investors for recognising quality.

The next phase may reward investors who can recognise quality at the right valuation.

And if the FMCG de-rating continues, some of India’s best consumer franchises may finally give patient investors exactly that opportunity.

Disclaimer: The stocks and valuations discussed above are for educational and informational purposes only and are not investment recommendations. Market prices, earnings and valuations can change rapidly. Investors should conduct their own research and consider their risk profile before investing.